Bausch + Lomb (BLCO) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 20, 2026, with voting on director elections, executive compensation, incentive plan amendment, and auditor appointment.

• 2025 saw record revenue growth, EBITDA margin expansion, and broad-based performance across all business segments.

• The company continues to focus on innovation, operational excellence, and long-term value creation.

Voting matters and shareholder proposals

• Shareholders will vote to elect ten directors, approve executive compensation (say-on-pay), amend the 2022 Omnibus Incentive Plan to add 25 million shares, and appoint PwC as auditor.

• Board recommends voting FOR all proposals.

• Shareholders may submit proposals and director nominations for the 2027 meeting, with specific deadlines and procedures outlined.

Board of directors and corporate governance

• Ten director nominees, nine of whom are independent, bring diverse expertise in finance, healthcare, operations, and governance.

• Board committees include Audit and Risk, Talent and Compensation, Nominating and Corporate Governance, and Science and Technology.

• Lead Independent Director role ensures independent oversight; annual board and committee evaluations are conducted.

• Share ownership guidelines require non-employee directors to hold equity valued at five times the annual cash retainer.